Kumar Aditya, Patwa Huned S, Nowak Richard J
Department of Neurology, Yale University School of Medicine, USA.
Department of Neurology, Yale University School of Medicine, USA.
J Neurol Sci. 2017 Apr 15;375:190-197. doi: 10.1016/j.jns.2017.01.061. Epub 2017 Jan 25.
Multifocal motor neuropathy (MMN) is a chronic immune-mediated disorder leading to slowly progressive muscle weakness and wasting. Current treatments are aimed at modulating the immune system in order to avoid further decline and to maintain functional status. Intravenous immunoglobulin (IVIg) is widely used in the treatment of immune-mediated disorders and is the only treatment approved for MMN. While patients do remain stable with maintenance IVIg treatment, most patients will slowly deteriorate over many years. The use of subcutaneous immunoglobulin (ScIg) is also gaining acceptance in this disease. The amount of axonal loss and the number of years without immunoglobulin (Ig) treatment appear to be associated with the permanence of weakness. We summarize the key literature to date that supports Ig use in the treatment of MMN.
多灶性运动神经病（MMN）是一种慢性免疫介导性疾病，可导致缓慢进展的肌肉无力和萎缩。目前的治疗旨在调节免疫系统，以避免病情进一步恶化并维持功能状态。静脉注射免疫球蛋白（IVIg）广泛用于治疗免疫介导性疾病，是唯一被批准用于MMN的治疗方法。虽然患者在接受维持性IVIg治疗后病情确实保持稳定，但大多数患者在多年后仍会缓慢恶化。皮下注射免疫球蛋白（ScIg）在这种疾病中的应用也越来越被认可。轴突损失的程度以及未接受免疫球蛋白（Ig）治疗的年数似乎与肌无力的持久性有关。我们总结了迄今为止支持Ig用于治疗MMN的关键文献。
